Condition
Epidermolytic Ichthyosis
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Completed2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06545695Phase 1Not Yet RecruitingPrimary
Epidermal Growth Factor Receptor Inhibition for Keratinopathies
NCT05312073Not ApplicableCompleted
Study of in Vivo and in Vitro Transcriptomic and Proteomic Signatures in Unhereditary Ichtyosis
NCT03041038Phase 2Completed
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
Showing all 3 trials